再燃前立腺癌に対する化学療法EtoposideおよびEtoposide+CDDPの治療効果

Abstract

再燃前立腺癌8例にエトポシド+CDDP併用およびエトポシド単独による化学療法を施行した.1) CDDPの併用療法は造血器障害, 腎機能障害, 重篤な合併症がなく, PSが0の症例に対し施行し, 3例が併用可能であった.2) 3例(2例が併用療法, 1例が単独療法)にPRが得られた.3)副作用は全身状態の良い症例では問題とならなかったが, 全身状態の悪い症例では強く出る可能性があり, 投与には十分注意する必要がある.4) CDDP併用可能症例に対しては, 試みる価値のあるレジメンであると思われた

Eight patients with recurrent prostate cancer were treated with Etoposide and CDDP or Etoposide alone. Etoposide was administered at a dose of 20 approximately 50 mg/m2/day for 5 consecutive days and CDDP was administered at a dose of 30 approximately 50 mg/m2 on the first day. Treatment was repeated every 3 or 4 weeks. Patients who were treated with combination chemotherapy (Etoposide + CDDP) were those with no hematological abnormalities, no renal dysfunction and good performance status. Three patients were treated with Etoposide and CDDP and five were treated with Etoposide alone. Clinical evaluation was as follows: 3 patients (2 with Etoposide and CDDP, 1 with Etoposide alone) had PR (37.5%) and 5 patients had PD (62.5%). We obtained the impression that lesions of soft tissue metastasis responded well to this chemotherapy and that this combination chemotherapy was more effective than Etoposide alone. Major complications were myelosuppression, gastrointestinal upset and loss of hair. However, they were tolerable in patients with good performance status. This combination chemotherapy (Etoposide + CDDP) seems to be worth further clinical trials to patients who were tolerable.